Site icon The Suffolk Journal

Ozempic Craze Sends Supermarket Sales Plummeting—You Won’t Believe What’s Missing!

The latest figures from retail analysts at Kantar suggest that the surge in GLP-1 weight-loss injections is starting to hit supermarket tills across the UK. As more households incorporate drugs like Ozempic into their routines, grocery volumes have recorded their first year-on-year decline this year. Below, we explore how this medical trend is reshaping consumer behaviour, what categories are most affected, and how retailers and brands might respond.

Rapid Uptake of GLP-1 Injections

According to Kantar’s recent data, the proportion of UK households with at least one member using a GLP-1 drug rose from 2.3% to 4.1% in just twelve months. This nearly doubled uptake is significant when considering the scale of the market:

Categories Feeling the Squeeze

Consumption patterns show that people on GLP-1 therapies are actively avoiding certain “host” foods:

As users modify longstanding snacking habits, supermarkets face reduced sales in both premium and budget ranges of these products. In some regions, this decline translates directly into empty shelf space and promotional markdowns to clear slow-moving stock.

Calorie Cuts and Appetite Changes

Research by weight-management service Voy indicates that individuals on GLP-1 injections often reduce their daily calorie intake by 25–35%. Key takeaways include:

With such significant calorie reductions, the ripple effect on weekly grocery baskets is clear—and likely to intensify as more patients begin treatment.

Market Size and Future Growth

The weight-loss drug market has ballooned to around $50 billion (£36 billion) by end-2024, and Morgan Stanley forecasts a doubling by 2030. Despite anticipated supply constraints, Novo Nordisk expects Ozempic revenues to grow by 14–16% in 2025 alone. These figures underscore a fundamental shift in consumer priorities—from indulgence to medical-guided health management.

Young Adults Leading the Trend

Mintel’s research highlights that 18–34-year-olds show the highest interest in GLP-1 prescriptions. Specific findings reveal:

This demographic tilt suggests supermarkets may see a sustained reduction in certain categories as younger shoppers continue prioritising drug-assisted weight control over traditional dietary patterns.

Long-Term Impact on Shopping Habits

While GLP-1 injections deliver rapid appetite suppression, questions remain about how long new eating habits will stick. If users revert to pre-treatment snacking once injections cease, grocery volumes may recover. However, anecdotal reports indicate many maintain healthier patterns even post-treatment.

Retailers face a strategic decision: will they adapt product assortments now in anticipation of lasting change, or wait for definitive consumption trends? Early adopters of healthier ranges or lower-calorie lines could gain a competitive edge.

Responsibility and Brand Messaging

With weight-loss drugs gaining traction, brands and supermarkets must tread carefully:

Chantel Kennaugh, Kantar’s nutrition expert, stresses that “host” foods depend on complementary categories—brands must innovate in low-calorie substitutes to retain customer loyalty.

Preparing for the New Grocery Landscape

As GLP-1 injections reshape appetites and shopping behaviour, the grocery industry enters uncharted territory. From reduced snack sales to emerging demands for high-protein, low-calorie options, supermarkets and brands will need to reassess their assortments and marketing strategies to meet evolving customer priorities.

In the coming months, tracking the interplay between prescription drug use and retail data will be critical. Supermarkets that align early with health-focused trends may capture new growth, while those slow to adapt risk falling behind in a rapidly changing food landscape.

Quitter la version mobile